Data gathered: November 21
AI Stock Analysis - BridgeBio Pharma (BBIO)
Analysis generated September 7, 2024. Powered by Chat GPT.
BridgeBio Pharma is a biotechnology company focusing on the development and commercialization of medicines targeting genetic diseases and cancers. The company's approach revolves around identifying promising targets and expediting their path to clinical development. BridgeBio Pharma's pipeline includes various phases of assets that target niche areas with significant unmet needs, positioning it as a pivotal participant in these therapeutic areas.
Stock Alerts - BridgeBio Pharma (BBIO)
 |
BridgeBio Pharma | November 21 Insider Alert: STEPHENSON BRIAN C is selling shares |
|
BridgeBio Pharma | November 18 Price is down by -5.1% in the last 24h. |
|
BridgeBio Pharma | November 13 Price is up by 5% in the last 24h. |
|
BridgeBio Pharma | November 12 Price is down by -5.6% in the last 24h. |
Alternative Data for BridgeBio Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 30,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | 55 | Sign up | Sign up | Sign up |
| Patents | 43 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,800 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 28 | Sign up | Sign up | Sign up |
| Business Outlook | 93 | Sign up | Sign up | Sign up |
| Linkedin Employees | 683 | Sign up | Sign up | Sign up |
About BridgeBio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
| Price | $23.24 |
| Target Price | Sign up |
| Volume | 1,290,000 |
| Market Cap | $4.26B |
| Year Range | $22.35 - $31.3 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136November 20 - Investing.com |
 |
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM MarketNovember 19 - Biztoc.com |
 |
BridgeBio Pharma (NASDAQ:BBIO) and International Stem Cell (OTCMKTS:ISCO) Head-To-Head ContrastNovember 18 - ETF Daily News |
 |
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell DramaticallyNovember 18 - Yahoo |
 |
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with AchondroplasiaNovember 18 - Investing.com |
|
State of New Jersey Common Pension Fund D Acquires 9,225 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)November 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.7M | 600,000 | 2.1M | -162M | -153M | 0.000 |
| Q2 '24 | 2.2M | 600,000 | 1.6M | -73M | -50M | -0.390 |
| Q1 '24 | 169M | 600,000 | 169M | -35M | -11M | -0.200 |
| Q4 '23 | 1.7M | 600,000 | -20M | -168M | -284M | -0.960 |
| Q3 '23 | 4.3M | 600,000 | -17M | -177M | -156M | -1.080 |
Insider Transactions View All
| STEPHENSON BRIAN C filed to sell 93,758 shares at $22.4. November 20 '24 |
| Kumar Neil filed to sell 4,897,443 shares at $22.8. November 20 '24 |
| Kumar Neil filed to sell 4,899,318 shares at $22.4. November 20 '24 |
| KRAVIS HENRY R filed to sell 25,260,971 shares at $25.8. September 17 '24 |
| STEPHENSON BRIAN C filed to sell 85,192 shares at $25.1. August 20 '24 |
Similar companies
Read more about BridgeBio Pharma (BBIO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of BridgeBio Pharma?
The Market Cap of BridgeBio Pharma is $4.26B.
What is the current stock price of BridgeBio Pharma?
Currently, the price of one share of BridgeBio Pharma stock is $23.24.
How can I analyze the BBIO stock price chart for investment decisions?
The BBIO stock price chart above provides a comprehensive visual representation of BridgeBio Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BridgeBio Pharma shares. Our platform offers an up-to-date BBIO stock price chart, along with technical data analysis and alternative data insights.
Does BBIO offer dividends to its shareholders?
As of our latest update, BridgeBio Pharma (BBIO) does not offer dividends to its shareholders. Investors interested in BridgeBio Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of BridgeBio Pharma?
Some of the similar stocks of BridgeBio Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.